Clinical trials: Subcutaneous Injection
Healthy
Study of Ixekizumab in Healthy Participants
The purpose of this study is to compare the tolerability of injections of each of 3 formulations of ixekizumab using a prefilled syringe.
- Trial name
- NCT03848403
- Testing
- Ixekizumab
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Heart Failure
A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects
This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part.
- Trial name
- NCT06700083
- Testing
- SHR-6934 injection
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Diabetes
To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects
This is a single-center, randomized, open, six-sequence, three-period crossover phase I clinical trial in healthy subjects to compare the PK/PD and safety profiles of single dose of HR20014, INS068, and INS062.
- Trial name
- NCT05887895
- Testing
- INS062 injection、INS068 injection、HR20014 injection
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers
The purpose of this study is to compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection
- Trial name
- NCT01894412
- Testing
- Etanercept (Enbrel), HD203
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hanwha Chemical
Healthy
Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.
- Trial name
- SPH (NCT01044836)
- Testing
- HD203
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hanwha Chemical
Healthy
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and safety of BCD-066 (darbepoetin alfa manufactured by CJSC BIOCAD, Russia) and Aranesp® (Amgen Europe B.V., Netherlands) in healthy…
- Trial name
- NCT02506881
- Testing
- Darbepoetin alfa
- Where
- Russia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biocad
Diabetes, Healthy
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynamics) after 21 days of daily…
- Trial name
- NCT00761540
- Testing
- liraglutide
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
To demonstrate that a single dose of Makena® delivered SQ via auto-injector has comparable bioavailability to a single IM injection of Makena®.
- Trial name
- NCT02940522
- Testing
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Where
- 5 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Primary Immune Thrombocytopenia (ITP)
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous…
- Trial name
- NCT06929299
- Testing
- STSA-1301 subcutaneous injection
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu BioJeTay Biotechnology Co., Ltd.
Body Weight Management
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of…
- Trial name
- NCT07826364
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Volunteer
A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
- Trial name
- NCT07413133
- Testing
- ABBV-8736
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects
It was a randomized, double-blind, placebo-controlled combined single ascending dose (SAD) and multiple ascending dose (MAD) study, evaluating the safety, tolerability and pharmacokinetics of TB001 after single and multiple…
- Trial name
- NCT05308940
- Testing
- TB001
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shenzhen Turier Biotech Co., Ltd
Healthy
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution…
- Trial name
- NCT05515601
- Testing
- Mirikizumab
- Where
- 6 sites in United States
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Hepatitis B
Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HT-102 (BM012) Injection in Healthy Subjects and Hepatitis B e Antigen-Negative Patients with Chronic Hepatitis B Virus Infection: A Randomized…
- Trial name
- NCT06744686
- Testing
- HT-102
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
Pharmacokinetics, Bioequivalence
A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System
A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system.
- Trial name
- NCT00614029
- Testing
- Sumatriptan (via Intraject System)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Zogenix, Inc.
Influenza Infection
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults
- Trial name
- NCT02313155
- Testing
- Subcutaneous injection of TAK-850, Intramuscular injection of TAK-850
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Type 2 Diabetes Mellitus (T2DM)
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design.
- Trial name
- NCT07630233
- Testing
- UBT38006, Insulin Degludec Injection, Insulin Icodec Injection
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Healthy Adult Subjects
A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.
The Goal of these study is to assess the comparative pharmacokinetics of Test Product (A): ADL-018 Injection 150 mg/mL solution in a single dose pre-filled autoinjector, manufactured by Kashiv Biosciences LLC, USA with Reference…
- Trial name
- NCT06929052
- Testing
- ADL-018 Autoinjector, ADL-018 Injection
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Asthma
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
The purpose of this study is to compare how two different formulations of the study medicine (GSK5784283) move through the body over time (pharmacokinetic [PK] study) in healthy adults.
- Trial name
- NCT07712393
- Testing
- GSK5784283
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity and Overweight
Phase Ia Clinical Study of HDM1005 Injection
This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult…
- Trial name
- NCT06640647
- Where
- China
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.